Bulletin
Investor Alert

New York Markets Close in:

Sept. 8, 2021, 9:11 a.m. EDT

The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI)

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)

or Cancel Already have a watchlist? Log In

Dyadic International, Inc. /zigman2/quotes/205986917/composite DYAI +1.08% generated research and development revenue of $937k in the quarter ended June 30, 2021 versus $524,000 in the second quarter of 2020, up 79% year over year. Cash and equivalents balance as of June 30, totaled $25.6 million. DYAI could be the most underappreciated name in the space at this point, for multiple reasons.

Novavax, Inc. /zigman2/quotes/202614340/composite NVAX +11.45% is another potential winner when it comes to alternatives to the new mRNA vaccine solutions. The company's core COVID-19 solution is said to be a step up in terms of manageability for a global population, and it is tracking well on the regulatory front. But the stock has already advanced massively on this narrative and more good news might be an exit door for early players.

According to its materials, the company focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.

Novavax, Inc. /zigman2/quotes/202614340/composite NVAX +11.45% recently announced that the U.S. Centers for Disease Control and Prevention (CDC) has provided updated guidance for those who have been vaccinated as part of a clinical trial in the U.S. The CDC guidance states that participants in the Novavax PREVENT-19 Phase 3 clinical trial meet the criteria to be considered fully vaccinated two weeks after they have completed the vaccine series.

"Novavax commends the CDC for its continued support for COVID-19 clinical trial volunteers, with this update providing clarity and guidance for participants in our PREVENT-19 Phase 3 clinical trial," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "We are grateful to all of our clinical trial participants who have helped create a safer future for all."

The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 16% in that timeframe. Shares of the stock have powered higher over the past month, rallying roughly 27% in that time on strong overall action.

Novavax, Inc. /zigman2/quotes/202614340/composite NVAX +11.45% managed to rope in revenues totaling $298M in overall sales during the company's most recently reported quarterly financial data — a figure that represents a rate of top line growth of 738.6%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($2.1B against $1.7B).

Other key players in the space include Moderna Inc /zigman2/quotes/205619834/composite MRNA +2.19% , Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.19% , BioNTech SE - ADR /zigman2/quotes/214419716/composite BNTX +4.39% , and AstraZeneca plc /zigman2/quotes/200304487/composite AZN -2.36% .

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer . We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact ir@edm.media.

The post The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI) appeared first on Wall Street PR .

COMTEX_392980514/2770/2021-09-08T09:10:49

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/205986917/composite
US : U.S.: Nasdaq
$ 3.59
+0.04 +1.08%
Volume: 1,026
Dec. 7, 2021 9:40a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$99.68 million
Rev. per Employee
$177,991
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 158.10
+16.24 +11.45%
Volume: 1.02M
Dec. 7, 2021 9:49a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$12.13 billion
Rev. per Employee
$601,262
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 158.10
+16.24 +11.45%
Volume: 1.02M
Dec. 7, 2021 9:49a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$12.13 billion
Rev. per Employee
$601,262
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 158.10
+16.24 +11.45%
Volume: 1.02M
Dec. 7, 2021 9:49a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$12.13 billion
Rev. per Employee
$601,262
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 271.13
+5.80 +2.19%
Volume: 1.38M
Dec. 7, 2021 9:49a
P/E Ratio
16.27
Dividend Yield
N/A
Market Cap
$124.36 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 51.58
+0.10 +0.19%
Volume: 4.42M
Dec. 7, 2021 9:49a
P/E Ratio
15.07
Dividend Yield
3.07%
Market Cap
$304.61 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 292.11
+12.28 +4.39%
Volume: 593,783
Dec. 7, 2021 9:49a
P/E Ratio
8.33
Dividend Yield
N/A
Market Cap
$67.86 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 54.11
-1.31 -2.36%
Volume: 746,566
Dec. 7, 2021 9:49a
P/E Ratio
85.24
Dividend Yield
2.54%
Market Cap
$171.48 billion
Rev. per Employee
$362,602
loading...

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.